Mindpeak sets standards with PD-L1 Cell Atlas

October 10, 2023
A refined approach for AI-assisted cancer diagnosis was developed by setting standards in the interpretation of scoring guidelines with a "PD-L1 Cell Atlas".

Hamburg (Germany), 10 October  2023 - Europe's leading provider of AI software for pathology, Mindpeak (Hamburg), has announced groundbreaking work with leading expert  pathologists to improve AI-assisted cancer diagnosis. The collaboration on a "PD-L1 Cell Atlas" marks a significant step in medical research and helps to advance the development and application of Artificial Intelligence (AI) in oncology biomarker readout for precision medicine.

A refined approach for AI-assisted cancer diagnosis was developed by setting standards in the interpretation of  scoring guidelines with a  "PD-L1 Cell Atlas", leading to improved interreader concordance among pathologists. This cell atlas will not only increase accuracy in the development of AI software for PD-L1 biomarker scoring, but will ultimately lead to better patient selection for more efficient immunotherapy using precision medicine drugs. The collaboration results were presented at ECP 2023, including the following authors: Prof. Sunil Badve (Winship Cancer Institute, Emory University Atlanta GA); Dr. George L. Kumar and Dr. Maria Karasarides (Bristol Myers Squibb Princeton NJ); Prof. Joseph Rüschoff and Prof. Hans-Ulrich Schildhaus (Discovery Life Sciences Biomarker Services GmbH Kassel); Dr. Tobias Lang, Felix Faber and Dr. Khalid Daifalla (Mindpeak GmbH Hamburg). 

The pathologists' expertise, particularly in difficult cases where distinguishing between cancer cells and immune cells is challenging, was combined with Mindpeak's leading expertise in AI software for biomarker scoring and was integrated into Mindpeak's AI software. This unique knowledge exchange between human experience and AI technology has significantly increased the effectiveness of cancer diagnosis.

Felix Faber, founder and CEO of Mindpeak, expressed his satisfaction with the groundbreaking collaboration: "I am very pleased that together with these outstanding experts we are able to contribute to the even better and more efficient application of AI in cancer diagnostics and the development of cancer therapies. This pioneering work forms an essential basis for the entire development of AI-assisted cancer treatment."

The results of the study have been presented at the 35th European Congress of Pathology from 9-13 September in Dublin under the title "A roadmap for single-cell annotation using artificial intelligence algorithms: analysis of programmed death ligand 1 immunohistochemistry expression in gastric cancer biopsies" by Prof. Sunil Badve, Head of the Department of Pathology and Laboratory Medicine at Emory University School of Medicine (Atlanta, USA). 

A roadmap for single-cell annotation using artificial intelligence algorithms: analysis of programmed death ligand 1 immunohistochemistry expression in gastric cancer biopsies.

About Mindpeak:

Mindpeak is Europe's leading provider of AI software for pathology. With a focus on tissue biomarker analysis and discovery, Mindpeak serves clinical laboratories and biopharma companies around the world. Mindpeak's algorithms were the first AI in digital pathology to be used in routine clinical diagnostics in the US and EU.

In the News

Related reading

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.
In the News
8 min read

Mindpeak in Oncology Times

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

As Patrick notes, the conversation must move from if to how. The science and technology already exist; now it’s about ensuring every patient, everywhere, can access and benefit from them.

At Mindpeak, we believe AI-powered pathology can help close that gap – supporting faster, more consistent insights that make precision medicine truly accessible.

In the News
8 min read

AI-Enabled Pathology: De-risking Oncology Drug Development

We are delighted to share that Aurélie Fugon, VP Predictive AI Solutions at Mindpeak, is featured in Life Science Daily News.

In her article, Aurélie outlines how AI-supported biomarker-driven strategies can reduce variability in pathology, improve the consistency of patient selection and help de-risk late-stage trials.

All key enablers of more reliable, data-rich clinical decision-making. With Aurélie’s leadership, we’re strengthening collaborations with pharma, biotech and clinical partners to help bring reproducible, scalable biomarker assessment into real-world research settings, shaping the future of predictive AI in precision oncology.

Read the full article here: https://lifesciencedaily.news/ai-enabled-pathology-de-risking-oncology-drug-development/

In the News
8 min read

United by Unique: Advancing Personalised Cancer Care on World Cancer Day

Every person with cancer is unique. So is every diagnosis - and every pathology sample that informs it.

This year’s World Cancer Day theme continues the focus on United by Unique, highlighting the importance of early detection, equitable access, and truly personalised care. It is a powerful reminder that behind every case is an individual with distinct biology, circumstances, and needs.

At Mindpeak, we believe precision medicine should be a right, not a privilege. Scientific and technological advances have transformed what is possible in cancer diagnostics. The challenge now is ensuring these innovations reach patients in ways that reflect their individuality.

Advanced AI models in digital pathology can help bridge this gap. By accelerating insights from complex tissue data and supporting clinicians with consistent, high-quality analysis, AI contributes to faster, more precise and more personalised decision-making.

On World Cancer Day, we stand with the global community in raising awareness and championing approaches that put people first. When we see the person before the disease, we move closer to a future where every individual’s uniqueness is recognized - and reflected - in their care.

Ready to advance your diagnostics

Connect with our team to explore how precision pathology works in your setting